Qualification Type: | PhD |
---|---|
Location: | Cambridge |
Funding for: | UK Students, EU Students, International Students |
Funding amount: | £21,500 per annum |
Hours: | Full Time |
Placed On: | 2nd October 2024 |
---|---|
Closes: | 4th November 2024 |
Reference: | PL43468 |
Applications are invited for 4-year PhD studentship based in the Department of Pharmacology, University of Cambridge and the new AstraZeneca Discovery Centre at Cambridge conducting research into how the microbiome contributes to chronic pain. The project will be jointly supervised by Dr David Bulmer (Cambridge) and Dr Fraser Welsh (AstraZeneca) and will provide the student with an opportunity to work across both sites, in addition to the broader multidisciplinary team of clinicians and academics investigating the microbiome and pain at the University and Medical School.
We have recently identified a pathogenic microbial signature which markedly deviates from household controls in people with chronic abdominal pain that can be corrected by dietary intervention. Metagenomic and metabolomic analysis supports a causative role for bacterial metabolites, which we will seek to evaluate in this studentship using functional assays of pain signalling, neuroepithelial and immune cell function, in conventional, and germ-free animals to recapitulate the dysbiotic microbial phenotype.
This PhD builds on a body of translational work from the Bulmer lab (Bautzova et al (2018) Sci Signal. 11(561); Higham et al (2024) Pain 165 (7): 1592-1604) and will utilise ex-vivo electrophysiological studies and Ca2+ imaging from mouse and human nociceptors.
Applicants must have or expect to obtain at least an upper 2nd class honours science degree (or equivalent), be highly motivated, capable of developing their own ideas, and keen to interact effectively with other lab members.
This position is open to UK citizens or overseas students who meet the UK residency requirements (home fees) or are able to augment the funds to cover the extra costs associated with international student fees through scholarships or funding schemes. Students will not be allowed to supplement fees via self funding.
The studentship comes with a stipend of £21,500 per annum and covers the University Composition Fee at the home student rate with effect from 1 October 2025.
How to apply:
All applications will need to be made through the University Application Portal. Please click 'Apply’ to be redirected to our website.
Please note that the course code for PhD applications to Pharmacology is BLPH22. Whilst making your online application please make clear that you are applying for; proposed supervisor Dr David Bulmer and title "How does the microbiota contribute to chronic pain?"
Your online application will need to include:
Please note that your application will not be considered complete and reviewed by the hiring supervisor until references have been completed.
Applications without the proposed supervisor section complete will not be considered.
The deadline for submission is 4th November 2024, with interviews likely to take place from the 11th November.
Informal enquires about the research project can be sent to Dr David Bulmer (dcb53@cam.ac.uk).
Informal enquires about application process can be sent to postgrad@phar.cam.ac.uk.
Please quote reference PL43468 on your application and in any correspondence about this vacancy.
The University actively supports equality, diversity and inclusion and encourages applications from all sections of society.
The University has a responsibility to ensure that all employees are eligible to live and work in the UK.
Type / Role:
Subject Area(s):
Location(s):